Cosmo Pharmaceuticals NV
SIX:COPN

Watchlist Manager
Cosmo Pharmaceuticals NV Logo
Cosmo Pharmaceuticals NV
SIX:COPN
Watchlist
Price: 62.8 CHF 1.45% Market Closed
Market Cap: 1B CHF
Have any thoughts about
Cosmo Pharmaceuticals NV?
Write Note

Cosmo Pharmaceuticals NV
Accrued Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Cosmo Pharmaceuticals NV
Accrued Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accrued Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Cosmo Pharmaceuticals NV
SIX:COPN
Accrued Liabilities
€5.3m
CAGR 3-Years
74%
CAGR 5-Years
49%
CAGR 10-Years
33%
Perrigo Company PLC
NYSE:PRGO
Accrued Liabilities
$533.1m
CAGR 3-Years
-3%
CAGR 5-Years
-6%
CAGR 10-Years
0%
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
Accrued Liabilities
$858m
CAGR 3-Years
14%
CAGR 5-Years
29%
CAGR 10-Years
18%
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
Accrued Liabilities
$34.6m
CAGR 3-Years
53%
CAGR 5-Years
23%
CAGR 10-Years
20%
G
GH Research PLC
NASDAQ:GHRS
Accrued Liabilities
$2.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Ovoca Bio PLC
LSE:OVB
Accrued Liabilities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Cosmo Pharmaceuticals NV
Glance View

Market Cap
1B CHF
Industry
Pharmaceuticals

Cosmo Pharmaceuticals NV engages in the development, manufacturing, and distribution of treatments for gastrointestinal diseases, endoscopy, colorectal cancer diagnosis, and colonoscopy. The company is headquartered in Dublin, Dublin and currently employs 290 full-time employees. The company went IPO on 2016-05-18. The firm develops therapies for gastrointestinal disorders. The firm's clinical development pipeline specifically addresses treatments for inflammatory bowel diseases, colorectal cancer diagnosis and colonoscopy. The company has developed a medical device for polyp excision and is developing a product for the detection of colon cancer. Its pipeline includes Lialda/Mezavant/Mesavancol, which is indicated for mild to moderate ulcerative colitis; Uceris/Cortiment, which is indicated for mild to moderate ulcerative colitis; Zacol NMX, which is indicated for intestinal disorders; Rifamycin SV MMX, which is indicated for Travelers' Diarrhea and uncomplicated diverticulitis, among others; CB-17-01, which is indicated for chromoendoscopy for colorectal cancer prevention in surveillance patients; CB-17-04, which is a sub mucosal injectable composition, and CB-01-12, which is an antibody anti-tumor necrosis factor (TNF) alpha drug.

COPN Intrinsic Value
139.73 CHF
Undervaluation 55%
Intrinsic Value
Price

See Also

What is Cosmo Pharmaceuticals NV's Accrued Liabilities?
Accrued Liabilities
5.3m EUR

Based on the financial report for Jun 30, 2024, Cosmo Pharmaceuticals NV's Accrued Liabilities amounts to 5.3m EUR.

What is Cosmo Pharmaceuticals NV's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 10Y
33%

Over the last year, the Accrued Liabilities growth was -28%. The average annual Accrued Liabilities growth rates for Cosmo Pharmaceuticals NV have been 74% over the past three years , 49% over the past five years , and 33% over the past ten years .

Back to Top